JP4443117B2 - Immunochromatographic specimen and diagnostic kit - Google Patents
Immunochromatographic specimen and diagnostic kit Download PDFInfo
- Publication number
- JP4443117B2 JP4443117B2 JP2002585986A JP2002585986A JP4443117B2 JP 4443117 B2 JP4443117 B2 JP 4443117B2 JP 2002585986 A JP2002585986 A JP 2002585986A JP 2002585986 A JP2002585986 A JP 2002585986A JP 4443117 B2 JP4443117 B2 JP 4443117B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- colored latex
- helicobacter pylori
- carrier
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000009007 Diagnostic Kit Methods 0.000 title claims description 8
- 238000012360 testing method Methods 0.000 claims description 105
- 239000004816 latex Substances 0.000 claims description 82
- 229920000126 latex Polymers 0.000 claims description 82
- 239000002245 particle Substances 0.000 claims description 46
- 229940037467 helicobacter pylori Drugs 0.000 claims description 36
- 239000007788 liquid Substances 0.000 claims description 35
- 241000590002 Helicobacter pylori Species 0.000 claims description 25
- 239000000872 buffer Substances 0.000 claims description 24
- 235000020183 skimmed milk Nutrition 0.000 claims description 21
- 229910021538 borax Inorganic materials 0.000 claims description 16
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 16
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims description 16
- 239000000020 Nitrocellulose Substances 0.000 claims description 15
- 229920001220 nitrocellulos Polymers 0.000 claims description 15
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 claims description 11
- 239000005695 Ammonium acetate Substances 0.000 claims description 11
- 229940043376 ammonium acetate Drugs 0.000 claims description 11
- 235000019257 ammonium acetate Nutrition 0.000 claims description 11
- 102000016938 Catalase Human genes 0.000 claims description 10
- 108010053835 Catalase Proteins 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 9
- 239000006185 dispersion Substances 0.000 claims description 7
- 230000003100 immobilizing effect Effects 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 239000004745 nonwoven fabric Substances 0.000 claims description 4
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 3
- 229940098773 bovine serum albumin Drugs 0.000 claims description 3
- 239000007974 sodium acetate buffer Substances 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 claims 4
- 239000000427 antigen Substances 0.000 description 29
- 102000036639 antigens Human genes 0.000 description 29
- 108091007433 antigens Proteins 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 14
- 239000007853 buffer solution Substances 0.000 description 14
- 239000002244 precipitate Substances 0.000 description 14
- 239000012086 standard solution Substances 0.000 description 14
- 238000001035 drying Methods 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 230000000873 masking effect Effects 0.000 description 12
- 238000005119 centrifugation Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 229920000136 polysorbate Polymers 0.000 description 11
- 229920001213 Polysorbate 20 Polymers 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 9
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 9
- 241000609499 Palicourea Species 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 238000003317 immunochromatography Methods 0.000 description 8
- 239000011521 glass Substances 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- -1 polypropylene Polymers 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 206010019375 Helicobacter infections Diseases 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 208000015877 Duodenal disease Diseases 0.000 description 2
- 101900104845 Helicobacter pylori Catalase Proteins 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000018556 stomach disease Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- 241000741973 Bifidobacterium breve DSM 20213 = JCM 1192 Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 241000590014 Helicobacter cinaedi Species 0.000 description 1
- 241000303608 Helicobacter felis ATCC 49179 Species 0.000 description 1
- 241001453258 Helicobacter hepaticus Species 0.000 description 1
- 241000590006 Helicobacter mustelae Species 0.000 description 1
- 241001473949 Helicobacter pylori NCTC 11637 = CCUG 17874 = ATCC 43504 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 241000404236 Zizina otis Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000005396 acrylic acid ester group Chemical group 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 1
- 201000011591 microinvasive gastric cancer Diseases 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229920003048 styrene butadiene rubber Polymers 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N vinyl-ethylene Natural products C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56922—Campylobacter
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Description
技術分野
本発明は、イムノクロマトグラフィー試験片及び診断キットに関する。
背景技術
ヘリコバクター・ピロリ(Hellcobacter pylori)はヒトの胃粘膜に見られる細菌である。ヘリコバクター・ピロリへの感染率は、社会経済状態と密接に関連しており、発展途上国ほど感染率が高く、先進国ほど感染率が低くなる傾向があるが、日本人の感染率は先進国の中でも際立って高く、40歳以上では80%の人が感染しているとも言われている。近年、ヘリコバクター・ピロリが胃潰瘍、十二指腸潰瘍、慢性胃炎、更には胃癌等のさまざまな胃、十二指腸疾患の原因となりうることが明らかになってきた。
ヘリコバクター・ピロリを除菌することにより、これらの疾患に罹患する可能性を低減できることが明らかになったために、ヘリコバクター・ピロリの除菌対象疾患について国際的な議論がなされ、現在では胃潰瘍、十二指腸潰瘍、胃悪性リンパ腫、早期胃癌切除後胃等が除菌の適応対象疾患として認知されている。
ヘリコバクター・ピロリの除菌療法が胃、十二指腸疾患の新しい治療法として認知されるのに伴い、我が国でも日本消化器病学会により治験ガイドラインが作成され、ヘリコバクター・ピロリ感染の存在診断と除菌判定法が示された(日本消化器病学会雑誌、96巻、199−207、1999年)。上記治験ガイドラインでは、存在診断は侵襲的検査法である胃部生検組織の培養、鏡検、ウレアーゼ試験にて行い、除菌判定は胃部生検組織の培養と鏡検及び非侵襲的検査法である尿素呼気試験を必須とすることが示されている。また、被験者が小児である等の特殊な場合、血中抗ヘリコバクター・ピロリ抗体検査と存在診断とを併用して判定を行うことが示されている。
しかし、これらのヘリコバクター・ピロリ感染の検査法には以下の問題点がある。侵襲的検査法は、胃内視鏡の挿入及び生検等により被験者が多大な苦痛を強いられることとなる。非侵襲的検査法では、被験者の苦痛は大幅に改善されるが、尿素呼気試験では、検査前の絶食が必要である。また、尿素呼気試験は、マススペクトルや赤外分光高度計等の装置が必要であり、特定の施設でしか実施できず、コストも高くなるという欠点がある。抗体検査は、除菌後も血中抗体価が長期にわたり高値であるので、除菌判定には適さない。従ってこれらの検査に代わる、非侵襲的で且つヘリコバクター・ピロリ感染を直接、特異的に精度良く検出できる検査方法が望まれている。
従来、消化管感染菌の直接検査法として消化管排泄物、特に糞便からの感染菌の選択培地を用いた分離培養が行われてきた。しかし、ヘリコバクター・ピロリに関しては数多くの試みにも拘らず、糞便から分離培養された報告はほとんどない。その理由として、ヘリコバクター・ピロリはin vitroで、低温、栄養欠乏、酸素欠乏等のように環境条件が悪化すると、通常のらせん状体から培養不能な球状体へ形態変化することから、下部消化管においても分離培養不能な球状体に変化していることが考えられる。
一方、抗原抗体反応に基づく免疫学的方法による糞便からのヘリコバクター・ピロリの直接検出に関して、ヘリコバクター・ピロリに対するポリクローナル抗体を用いたイムノアッセイにより糞便等の排泄物検体中のヘリコバクター・ピロリを検出する方法が報告されている(J.Clin.Microbiol.、33巻、2162−2165、1995年、特開平10−10128号公報(特許第3043999号))。
しかし、ポリクローナル抗体は、一般に交差反応性があり、特異性が劣るうえ、抗血清のロット毎に抗体価や特異性が変動する欠点があるので、ポリクローナル抗体を用いた診断薬の製造は、本質的に品質管理が難しいという問題点がある。現実に、特許第3043999号の特許権者であるメリディアン社により製造されたポリクローナル抗体を用いた糞便中ヘリコバクター・ピロリ抗原検出キット「HpSA」に関しては、偽陰性の出現や特異性の低さが問題となっている(Medical Tribune、4−5、1999年6月3日号;Am.J.Gastroenterol.、94巻、1830−1833、1999年)。
発明の要約
本発明は、上記現状に鑑み、糞便を検体として用い、感度よくヘリコバクター・ピロリへの感染を判定することができるイムノクロマトグラフィー試験片及び診断キットを提供することを目的とするものである。
本発明は、短冊形状の抗体固相化支持体の下端上に下から順に着色ラテックス標識物保持担体、及び、濾紙からなる液体試料吸収用担体が積層され、一方、前記抗体固相化支持体の上端上に濾紙よりなる吸水性担体が積層されてなる積層体からなるイムノクロマトグラフィー試験片であって、前記抗体固相化支持体は、ニトロセルロースシート上にヘリコバクター・ピロリのネイティブなカタラーゼと抗原抗体反応を行うモノクローナル抗体が固相化されてなり、前記着色ラテックス粒子標識物保持担体は、着色ラテックス粒子にヘリコバクター・ピロリのネイティブなカタラーゼと抗原抗体反応を行うモノクローナル抗体を固定化してなる着色ラテックス粒子標識抗ヘリコバクター・ピロリ抗体が不織布に含浸されてなるイムノクロマトグラフィー試験片である。
発明の詳細な開示
以下に本発明を詳述する。
本発明のイムノクロマトグラフィー試験片は、短冊形状の抗体固相化支持体の下端上に下から順に着色ラテックス標識物保持担体、及び、濾紙からなる液体試料吸収用担体が積層され、一方、前記抗体固相化支持体の上端上に濾紙よりなる吸水性担体が積層されてなる積層体からなるものである。
上記抗体固相化支持体は、ニトロセルロースシート上にヘリコバクター・ピロリのネイティブなカタラーゼと抗原抗体反応を行うモノクローナル抗体(以下、抗Hpモノクローナル抗体ともいう)が固相化されているものである。
上記抗Hpモノクローナル抗体としては、例えば、ハイブリドーマ21G2(FERM BP−7336)、41A5(FERM BP−7337)、又は、82B9(FERM BP−7338)、31A3(FERM P−18329)、又は、82A3(FERM P−18328)から産生されるモノクローナル抗体を挙げることができる。
固相化された抗Hpモノクローナル抗体は、検体中のヘリコバクター・ピロリのカタラーゼを認識し、カタラーゼと着色ラテックス粒子標識抗ヘリコバクター・ピロリ抗体との複合体を捕捉することができる。従って、抗Hpモノクローナル抗体が抗体固相化支持体上に線上に固相化されていれば、そのラインが着色ラテックス粒子により浮かび上がることとなる。
上記抗体固相化支持体は、抗Hpモノクローナル抗体を分散させた緩衝液を、ニトロセルロースシートに塗布し、乾燥することにより得ることができる。
上記緩衝液としては特に限定されないが、得られたイムノクロマトグラフィー試験片のヘリコバクター・ピロリの検出感度の点から、酢酸ナトリウム緩衝液、酢酸アンモニウム緩衝液、リン酸ナトリウム緩衝液等が好ましい。
上記抗体固相化支持体には、更に、抗Hpモノクローナル抗体に対する抗体、ヘリコバクター・ピロリのカタラーゼ、コントロールライン用着色ラテックス粒子標識物に対して特異的に結合する物質が固相化されていてもよい。これにより、イムノクロマトグラフィー試験が正常に行われたかどうかを判定することができる。
上記着色ラテックス粒子標識物保持担体は、着色ラテックス粒子にヘリコバクター・ピロリのネイティブなカタラーゼと抗原抗体反応を行うモノクローナル抗体を固定化してなる着色ラテックス粒子標識抗ヘリコバクター・ピロリ抗体が不織布に含浸されているものである。
上記不織布としては特に限定されず、例えば、ポリエステル、レーヨン、ポリプロピレン、セルロース、パルプ等からなるものを挙げることができる。
上記ラテックス粒子としては特に限定されず、例えば、スチレン、塩化ビニル、アクリロニトリル、酢酸ビニル、アクリル酸エステル、メタクリル酸エステル等のビニル系モノマーの単一重合体や共重合体;スチレン−ブタジエン共重合体、メチルメタクリレート−ブタジエン共重合体等のブタジエン系共重合体等に着色してなる微粒子を挙げることができる。これらのうち、抗体又は抗原の吸着性に優れており、かつ、生物学的活性を長期間安定に保持できる等の理由から、ポリスチレン系のラテックス粒子が好適に用いられる。
抗Hpモノクローナル抗体を上記着色ラテックス粒子に担持する方法としては特に限定されず、例えば、物理的又は化学的に吸着させる方法等により行うことができる。
上記着色ラテックス粒子標識物保持担体には、更に、異なる色に着色された着色ラテックスに抗体等を固定した第2着色ラテックス粒子標識物が含浸されていてもよい。このような第2着色ラテックス粒子標識物はコントロールライン用マーカーとして用いることができる。
上記着色ラテックス粒子標識物保持担体は、スキムミルク又はウシ血清アルブミンでブロッキングされていることが好ましい。これにより、非特異的な反応を抑制することができ、陰性の検体を陽性と判定する偽陽性をなくすことができる。
上記液体試料吸収用担体は、酸性物質吸着能を保持していることが好ましい。糞便中の色素や夾雑物は酸性物質が多い。酸性物質吸着能が保持されていることにより、ヘリコバクター・ピロリに対して優れた検出感度・特異度を発現することができる。このような酸性物質吸着能が保持されている液体試料吸収用担体としては、市販品を用いることができ、例えば、DE81(ワットマン社製)等を挙げることができる。
本発明のイムノクロマトグラフィー試験片は、更に、プラスチック等よりなる基体に固定されて強度が付与されていてもよく、また、保護のために表面に透明なテープ等が貼られていてもよい。
本発明のイムノクロマトグラフィー試験片の製造方法としては特に限定されず、例えば、以下の方法により得ることができる。
(1)抗体固相化支持体の作製
抗Hpモノクローナル抗体及び抗ウサギIgG抗体を線状に固相化した抗体固相化支持体を作製するために、ニトロセルロースシート(ワットマン社製)を5mm×20mmに裁断し、その下端より10mmの位置にモノクローナル抗体21G2の溶液、15mmの位置に抗ウサギIgGヤギポリクローナル抗体(Cappel社製)の溶液をバイオジェットQ3000(Biodot社製)を用いて塗布した。室温で2時間乾燥後、1%スキムミルク(Difco社製)−0.1%ツィーン20−PBSに10分浸漬しマスキングを行った。その後、充分に乾燥した。
(2)着色ラテックス粒子標識物保持担体の調製
a.赤色ラテックス粒子標識抗ヘリコバクター・ピロリ抗体
赤色ラテックス粒子分散液(PL−Latex、10%、450nm、Polymer Laboratories社製)300μLにPBS1.2mLを加え、13000rpm、5分間遠心分離を行った。沈渣にモノクローナル抗体21G2溶液(5mg/mL)1.5mLを加え、充分混和して、室温、1時間反応を行った。未反応のモノクローナル抗体を除去するため、13000rpm、5分間遠心分離を行い、沈渣をPBS1.5mLに懸濁し、再度遠心分離を行った。1%スキムミルク1mLを加え、室温、1時間反応させてマスキングを行った。その後、13000rpm、5分間遠心分離を行い、沈渣を1%スキムミルク−0.01%アジ化ナトリウムを含むPBS1.5mLに懸濁した。
b.青色ラテックス粒子標識ウサギIgG
青色ラテックス粒子分散液(PL−Latex、10%、450nm、Polymer Laboratories社製)及びウサギIgG(0.5mg/mL、Cappel社製)を用いて上記と同様な操作で青色ラテックス粒子標識ウサギIgGを調製した。
c.着色ラテックス粒子標識物保持担体
上記2種類の着色ラテックス粒子標識抗体を等量混和し、ベンリーゼ(商標登録)不織布(旭化成社製)5mm×5mmに10μL含浸させ、通風乾燥した。
(3)イムノクロマトグラフィー試験片の作製
抗体固相化支持体の下端から2.5mmの位置まで着色ラテックス標識物保持担体を重ねた。更に、着色ラテックス標識物保持担体上に液体試料吸収用担体(3MM Chr、ワットマン社製)を下端から2.5mmの位置まで重ねた。また、抗体固相化支持体の上端から2mmの位置まで吸水性担体(3MM Chr、ワットマン社製)を重ね、最後に透明なテープを上部に貼り固定してイムノクロマトグラフィー試験片とした。
本発明のイムノクロマトグラフィー試験片が含まれている診断キットもまた、本発明の1つである。
上記診断キットには、本発明のイムノクロマトグラフィー試験片以外に、例えば、ウェル、陽性コントロール、陰性コントロール、便懸濁用緩衝液、濃縮洗浄液等が含まれていてもよい。
上記便懸濁用緩衝液としては特に限定されないが、検出感度に優れる点より、PBS及び/又はホウ酸ナトリウム緩衝液が好ましい。
発明を実施するための最良の形態
以下に実施例を掲げて本発明を更に詳しく説明するが、本発明はこれら実施例のみに限定されるものではない。
(実施例1)抗体固相化用緩衝液の検討
(1)抗体固相化支持体の作製
3%メタノールを含む10mMの各緩衝液(リン酸ナトリウム(pH5〜8)、酢酸ナトリウム(pH4〜6)、酢酸アンモニウム(pH4〜6)、クエン酸ナトリウム(pH4〜6)、トリス塩酸(pH7〜9)、ホウ酸ナトリウム(pH8〜10)、塩化アンモニウム(pH8〜11)、炭酸アンモニウム(pH8〜10))を調製し、抗ヘリコバクター・ピロリ(Hp)モノクローナル抗体21G2を1mg/mLの濃度に添加した。ニトロセルロースシート(ワットマン社製)を5mm×20mmに裁断し、その下端から10mmの位置にテストライン用として各緩衝液で調製した抗Hpモノクローナル抗体21G2溶液を、15mmの位置にコントロールライン用として抗マウスIgGポリクローナル抗体(Cappel社製)(1mg/mL)を、バイオジェットQ3000(Biodot社製)を用いて線状に塗布して固相化した。室温で2時間乾燥後、1%スキムミルク(Difco社製)−0.1%ツィーン20−PBSに10分浸漬しマスキングを行った。その後、充分に乾燥した。
(2)着色ラテックス粒子標識抗体の作製
赤色ラテックス粒子分散液(PL−Latex、10%、粒子径450nm、ポリマーラボトリーズ社製)100μLを、10000rpm、5分間遠心分離を行った。沈渣に抗Hpモノクローナル抗体21G2溶液(1mg/mL)1mL加え、充分混和して、室温、1時間反応を行った。未反応のモノクローナル抗体を除去するため、10000rpm、5分間遠心分離を行い、沈渣をPBS1mLに懸濁し、再度遠心分離を行った。1%スキムミルク1mLを加え、室温、1時間反応させてマスキングを行った。その後、10000rpm、5分間遠心分離を行い、1%スキムミルク−0.01%アジ化ナトリウムを含むPBS1mLに沈渣を懸濁した。
(3)イムノクロマトグラフィー試験片の作製
(1)で作製したそれぞれの抗体固相化支持体の下端から2mmの位置まで5mm×10mmに裁断したグラスフィルター(ワットマン社製)を重ねた。更に、グラスフィルター上に液体試料吸収用担体(C/P−30、ワットマン社製)を下端から2.5mmの位置まで重ねた。また、抗体固相化支持体の上端から2mmの位置まで吸水性担体(3MM Chr、ワットマン社製)を重ね、最後に透明なテープを上部に貼り固定してイムノクロマトグラフィー試験片とした。
(4)Hp標準抗原の調製
5%ウマ脱繊血を含むブレイン ハート インヒュージョン寒天培地(ディフコ社製)150枚にヘリコバクター・ピロリATCC43504株を37℃、4日間、微好気培養した。培養後、菌体を集め、PBS 40mLで懸濁後、3000rpm、20分間遠心分離した。沈渣を0.5%ホルマリン含有PBS 40mLに懸濁し、4℃、1晩放置して不活化した。不活化した菌体は、PBS 40mLにて3回洗浄し、ホルマリンを除去した後、同量のPBSに再懸濁した。菌液の濁度(540nmでの吸光度)及び総菌数(計算盤を用いた顕微鏡観察)を確認した後、超音波処理により破砕した。菌体破砕物は、3000rpm、20分間遠心分離し、その上清を更に30000rpm、30分間超遠心した。この上清を0.2μmのフィルターにてろ過してHp標準抗原とした。
(5)Hp抗原標準液の測定
0.5%BSA−0.02%ツィーン20−PBSで希釈したHp抗原標準液50μLと、(2)で作製した着色ラテックス粒子標識抗体液10μLとを混合した液に(3)で得られたイムノクロマトグラフィー試験片の液体試料吸収用担体部を浸漬して展開させ、10分後に目視判定をした。その結果を表1に示した。「+」はテストラインの赤いラインを確認できること、「±」はテストラインの赤い色が確認できるが非常に色が薄いこと、「−」はテストラインの赤いラインを確認できないことを示す。酢酸ナトリウム緩衝液(pH5)及び酢酸アンモニウム緩衝液(pH5)を用いてテストラインを固相化することで、Hp抗原標準液0.5μg/mLまで判定可能であった。
(実施例2)着色ラテックス標識物保持担体のブロッキング溶液の比較
(1)抗体固相化支持体の作製
ニトロセルロースシート(ワットマン社製)を5mm×20mmに裁断し、その下端から10mmの位置にテストライン用として3%メタノールを含む10mM酢酸アンモニウム(pH5)緩衝液で調製した抗Hpモノクローナル抗体溶液(1mg/mL)を、15mmの位置にコントロールライン用として抗マウスIgGポリクローナル抗体(Cappel社製)(1mg/mL)をバイオジェットQ3000(Biodot社製)を用いて線状に塗布して固相化した。室温で2時間乾燥後、1%スキムミルク(Difco社製)−0.1%ツィーン20−PBSに10分浸漬しマスキングを行った。その後、充分に乾燥した。
(2)着色ラテックス標識物保持担体作製時のブロッキング溶液の比較
ポリビニルアルコール(以下PVAとする、和光純薬社製)、ポリビニルピロリドンK15(以下PVPとする、東京化成社製)、ツィーン20、トライトンX−100、ドデシル硫酸ナトリウム(以下SDSとする)、スキムミルク、ウシ血清アルブミン(以下BSAとする)を用いて、着色ラテックス標識物保持用担体であるグラスファイバーフィルターのブロッキングに及ぼす影響を調べた。5mm×10mmに裁断したグラスフィルターを、1%濃度に調製したPVA、PVP、ツィーン20、トライトンX−100、SDS、スキムミルク、BSAにそれぞれ5分間浸漬し、ブロッキングを行った。室温、2時間乾燥後、実施例1で作製した着色ラテックス粒子標識抗体を10μL塗布した。その後、充分に乾燥し着色ラテックス標識物保持担体とした。
(3)イムノクロマトグラフィー試験片の作製
(1)で作製した抗体固相化支持体の下端から2mmの位置まで(2)で作製したそれぞれの着色ラテックス標識抗体保持担体を重ねた。更に、着色ラテックス保持担体上に液体試料吸収用担体(C/P−30、ワットマン社製)を下端から2.5mmの位置まで重ねた。また、抗体固相化支持体の上端から2mmの位置まで吸水性担体(3MM Chr、ワットマン社製)を重ね、最後に透明なテープを上部に貼り固定してイムノクロマトグラフィー試験片とした。
(4)糞便検体中ヘリコバクター・ピロリの検出
Hp陽性5名、Hp陰性5名の糞便検体0.1gを0.5%BSA−0.02%ツィーン20−PBS 2mLに懸濁した。3000rpm、1分間遠心分離して夾雑物を除去し、上清50μLを(4)で作製したイムノクロマトグラフィー試験片の液体試料吸収用担体部に滴下した。10分後に目視判定した。その結果を表2に示した。「+」はテストラインの赤いラインを確認できること、「±」はテストラインの赤い色が確認できるが非常に色が薄いこと、「−」はテストラインの赤いラインを確認できないこと、「*」は、ラテックス標識抗体が凝集し、テストラインまで展開できないことを示す。BSA又はスキムミルクによってブロッキングしたグラスファイバーフィルターが、陽性検体では全例陽性、陰性検体では全例陰性と判定できた。
(実施例3)液体試料吸収用担体の比較
(1)着色ラテックス標識物保持担体の作製
5mm×10mmに裁断したグラスフィルターを、1%濃度に調製したスキムミルクに5分間浸漬し、ブロッキングを行った。室温、2時間乾燥後、実施例1で作製した着色ラテックス粒子標識抗体を10μL塗布した。その後、充分に乾燥し着色ラテックス標識物保持担体とした。
(2)液体試料吸収用担体の比較
実施例2で作製した抗体固相化支持体の下端から2mmの位置まで(1)で作製した着色ラテックス標識物保持担体を重ねた。更に、着色ラテックス標識物保持担体上に液体試料吸収用担体としてC/P−30(ワットマン社製)、P81(ワットマン社製)、C/DE30(ワットマン社製)、DE81(ワットマン社製)、GF/QA30(ワットマン社製)を下端から2.5mmの位置まで重ねた。また、抗体固相化支持体の上端から2mmの位置まで吸水性担体(3MM Chr、ワットマン社製)を重ね、最後に透明なテープを上部に貼り固定してイムノクロマトグラフィー試験片とした。
(3)Hp抗原標準液の測定
0.5%BSA−0.02%ツィーン20−PBSで希釈したHp抗原標準液50μLを上記で得られたイムノクロマトグラフィー試験片の液体試料吸収用担体部に滴下して展開させ、10分後に目視判定をした。その結果を表3に示した。「+」はテストラインの赤いラインを確認できること、「±」はテストラインの赤い色が確認できるが非常に色が薄いこと、「−」はテストラインの赤いラインを確認できないことを示す。液体試料吸収用担体としてDE81を用いるとHp抗原濃度0.1μg/mLまで判定可能であった。
(実施例4)Hp検出に及ぼす便懸濁用緩衝液の組成の影響
(1)イムノクロマトグラフィー試験片の作製
実施例2で作製した抗体固相化支持体の下端から2mmの位置まで実施例3で作製した着色ラテックス標識物保持担体を重ねた。更に、着色ラテックス標識物保持担体上に液体試料吸収用担体としてDE81(ワットマン社製)を下端から2.5mmの位置まで重ねた。また、抗体固相化支持体の上端から2mmの位置まで吸水性担体(3MM Chr、ワットマン社製)を重ね、最後に透明なテープを上部に貼り固定してイムノクロマトグラフィー試験片とした。
(2)Hp標準抗原検出に及ぼす便懸濁用緩衝液の組成の影響
0.5%BSA−0.02%ツィーン20−PBS及び0.5%BSA−0.02%ツィーン20を含む150mMの各緩衝液(リン酸ナトリウム(pH5〜8)、ホウ酸ナトリウム(pH8〜10))で希釈したHp抗原標準液50μLを上記で得られたイムノクロマトグラフィー試験片の液体試料吸収用担体部に滴下して展開させ、10分後に目視判定をした。その結果を表4に示した。「+」はテストラインの赤いラインを確認できること、「±」はテストラインの赤い色が確認できるが非常に色が薄いこと、「−」はテストラインの赤いラインを確認できないことを示す。便懸濁用緩衝液にPBS及びホウ酸ナトリウム緩衝液を用いるとHp抗原濃度0.1μg/mLまで正確に判定可能であった。
(実施例5)抗Hpモノクローナル抗体82B9を用いたイムノクロマトグラフィー試験片の作製
(1)抗体固相化支持体の作製
3%メタノールを含む10mMの各緩衝液(リン酸ナトリウム(pH5〜8)、酢酸アンモニウム(pH4〜6)、ホウ酸ナトリウム(pH8〜10))を調製し、抗ヘリコバクター・ピロリ(Hp)モノクローナル抗体82B9を1mg/mLの濃度に添加した。ニトロセルロースシート(ワットマン社製)を5mm×20mmに裁断し、その下端から10mmの位置にテストライン用として各緩衝液で調製した抗Hpモノクローナル抗体82B9溶液を、15mmの位置にコントロールライン用として抗マウスIgGポリクローナル抗体(Cappel社製)(1mg/mL)を、バイオジェットQ3000(Biodot社製)を用いて線状に塗布して固相化した。室温で2時間乾燥後、1%スキムミルク(Difco社製)−0.1%ツィーン20−PBSに10分浸漬しマスキングを行った。その後、充分に乾燥した。
(2)着色ラテックス粒子標識抗体の作製
赤色ラテックス粒子分散液(PL−Latex、10%、粒子径450nm、ポリマーラボトリーズ社製)100μLを、10000rpm、5分間遠心分離を行った。沈渣に抗Hpモノクローナル抗体82B9溶液(1mg/mL)1mL加え、充分混和して、室温、1時間反応を行った。未反応のモノクローナル抗体を除去するため、10000rpm、5分間遠心分離を行い、沈渣をPBS1mLに懸濁し、再度遠心分離を行った。1%スキムミルク1mLを加え、室温、1時間反応させてマスキングを行った。その後、10000rpm、5分間遠心分離を行い、1%スキムミルク−0.01%アジ化ナトリウムを含むPBS1mLに沈渣を懸濁した。
(3)着色ラテックス標識物保持担体の作製
5mm×10mmに裁断したグラスフィルターを、1%濃度に調製したスキムミルクに5分間浸漬し、ブロッキングを行った。室温、2時間乾燥後、(2)で作製した着色ラテックス粒子標識抗体を10μL塗布した。その後、充分に乾燥し着色ラテックス標識物保持担体とした。
(4)イムノクロマトグラフィー試験片の作製
(1)で作製したそれぞれの抗体固相化支持体の下端から2mmの位置まで(3)で作製した着色ラテックス標識物保持担体を重ねた。更に、着色ラテックス標識物保持担体上に液体試料吸収用担体としてDE81(ワットマン社製)を下端から2.5mmの位置まで重ねた。また、抗体固相化支持体の上端から2mmの位置まで吸水性担体(3MM Chr、ワットマン社製)を重ね、最後に透明なテープを上部に貼り固定してイムノクロマトグラフィー試験片とした。
(5)Hp抗原標準液の測定
0.5%BSA−0.02%ツィーン20を含む150mMホウ酸ナトリウム緩衝液(pH8)で希釈したHp抗原標準液50μLを上記で得られたイムノクロマトグラフィー試験片の液体試料吸収用担体部に滴下して展開させ、10分後に目視判定をした。その結果を表5に示す。「+」はテストラインの赤いラインを確認できること、「±」はテストラインの赤い色が確認できるが非常に色が薄いこと、「−」はテストラインの赤いラインを確認できないことを示す。リン酸ナトリウム緩衝液(pH6)を用いてテストラインを固相化することで、Hp抗原濃度0.25μg/mLまで正確に判定可能であった。
(実施例6)抗Hpモノクローナル抗体41A5を用いたイムノクロマトグラフィー試験片の作製
(1)抗体固相化支持体の作製
3%メタノールを含む10mMの各緩衝液(リン酸ナトリウム(pH5〜8)、酢酸アンモニウム(pH4〜6)、ホウ酸ナトリウム(pH8〜10))を調製し、抗ヘリコバクター・ピロリ(Hp)モノクローナル抗体41A5を1mg/mLの濃度に添加した。ニトロセルロースシート(ワットマン社製)を5mm×20mmに裁断し、その下端から10mmの位置にテストライン用として各緩衝液で調製した抗Hpモノクローナル抗体41A5溶液を、15mmの位置にコントロールライン用として抗マウスIgGポリクローナル抗体(Cappel社製)(1mg/mL)を、バイオジェットQ3000(Biodot社製)を用いて線状に塗布して固相化した。室温で2時間乾燥後、1%スキムミルク(Difco社製)−0.1%ツィーン20−PBSに10分浸漬しマスキングを行った。その後、充分に乾燥した。
(2)着色ラテックス粒子標識抗体の作製
赤色ラテックス粒子分散液(PL−Latex、10%、粒子径450nm、ポリマーラボトリーズ社製)100μLを、10000rpm、5分間遠心分離を行った。沈渣に抗Hpモノクローナル抗体41A5溶液(1mg/mL)1mL加え、充分混和して、室温、1時間反応を行った。未反応のモノクローナル抗体を除去するため、10000rpm、5分間遠心分離を行い、沈渣をPBS1mLに懸濁し、再度遠心分離を行った。1%スキムミルク1mLを加え、室温、1時間反応させてマスキングを行った。その後、10000rpm、5分間遠心分離を行い、1%スキムミルク−0.01%アジ化ナトリウムを含むPBS1mLに沈渣を懸濁した。
(3)着色ラテックス標識物保持担体の作製
5mm×10mmに裁断したグラスフィルターを、1%濃度に調製したスキムミルクに5分間浸漬し、ブロッキングを行った。室温、2時間乾燥後、(2)で作製した着色ラテックス粒子標識抗体を10μL塗布した。その後、充分に乾燥し着色ラテックス標識物保持担体とした。
(4)イムノクロマトグラフィー試験片の作製
(1)で作製したそれぞれの抗体固相化支持体の下端から2mmの位置まで(3)で作製した着色ラテックス標識物保持担体を重ねた。更に、着色ラテックス標識物保持担体上に液体試料吸収用担体としてDE81(ワットマン社製)を下端から2.5mmの位置まで重ねた。また、抗体固相化支持体の上端から2mmの位置まで吸水性担体(3MM Chr、ワットマン社製)を重ね、最後に透明なテープを上部に貼り固定してイムノクロマトグラフィー試験片とした。
(5)Hp抗原標準液の測定
0.5%BSA−0.02%ツィーン20を含む150mMホウ酸ナトリウム緩衝液(pH8)で希釈したHp抗原標準液50μLを上記で得られたイムノクロマトグラフィー試験片の液体試料吸収用担体部に滴下して展開させ、10分後に目視判定をした。その結果を表5に示す。「+」はテストラインの赤いラインを確認できること、「−」はテストラインの赤いラインを確認できないことを示す。酢酸アンモニウム緩衝液(pH4及びpH5)を用いてテストラインを固相化することで、Hp抗原濃度0.25μg/mLまで正確に判定可能であった。
(実施例7)抗Hpモノクローナル抗体31A3および抗体21G2を用いたイムノクロマトグラフィー試験片の作製
(1)抗体固相化支持体の作製
3%メタノールを含む10mMの各緩衝液(リン酸ナトリウム(pH5〜8)、酢酸アンモニウム(pH4〜6)、ホウ酸ナトリウム(pH8〜10))を調製し、抗ヘリコバクター・ピロリ(Hp)モノクローナル抗体31A3を1mg/mlの濃度に添加した。ニトロセルロースシート(ワットマン社製)を5mm×20mmに裁断し、その下端から10mmの位置にテストライン用として各緩衝液で調製した抗Hpモノクローナル抗体溶液を、15mmの位置にコントロールライン用として抗マウスIgGポリクローナル抗体(Cappel社製)(1mg/ml)を、バイオジェットQ3000(Biodot社製)を用いて線状に塗布して固相化した。室温で2時間乾燥後、1%スキムミルク(Difco社製)−0.1%ツィーン20−PBSに10分浸漬しマスキングを行った。その後、充分に乾燥した。
(2)イムノクロマトグラフィー試験片の作製
(1)で作製したそれぞれの抗体固相化支持体の下端から2mmの位置まで実施例3(1)で作製した抗体21G2着色ラテックス標識物保持担体を重ねた。更に、着色ラテックス標識物保持担体上に液体試料吸収用担体としてDE81(ワットマン社製)を下端から2.5mmの位置まで重ねた。また、抗体固相化支持体の上端から2mmの位置まで吸水性担体(3MM Chr、ワットマン社製)を重ね、最後に透明なテープを上部に貼り固定してイムノクロマトグラフィー試験片とした。
(3)Hp抗原標準液の測定
0.5%BSA−0.02%ツィーン20を含む150mMホウ酸ナトリウム緩衝液(pH8)で希釈したHp抗原標準液50μLを上記で得られたイムノクロマトグラフィー試験片の液体試料吸収用担体部に滴下して展開させ、10分後に目視判定をした。その結果を表7に示す。「+」はテストラインの赤いラインを確認できること、「±」はテストラインの赤い色が確認できるが非常に色が薄いこと、「−」はテストラインの赤いラインを確認できないことを示す。リン酸ナトリウム緩衝液(pH7)を用いてテストラインを固相化することで、Hp抗原濃度0.25μg/mlまで正確に判定可能であった。
(実施例8)抗Hpモノクローナル抗体82A3を用いたイムノクロマトグラフィー試験片の作製
(1)抗体固相化支持体の作製
3%メタノールを含む10mMの各緩衝液(リン酸ナトリウム(pH5〜8)、酢酸アンモニウム(pH4〜6)、ホウ酸ナトリウム(pH8〜10))を調製し、抗ヘリコバクター・ピロリ(Hp)モノクローナル抗体82A3を1mg/mlの濃度に添加した。ニトロセルロースシート(ワットマン社製)を5mm×20mmに裁断し、その下端から10mmの位置にテストライン用として各緩衝液で調製した抗Hpモノクローナル抗体溶液を、15mmの位置にコントロールライン用として抗マウスIgGポリクローナル抗体(Cappel社製)(1mg/ml)を、バイオジェットQ3000(Biodot社製)を用いて線状に塗布して固相化した。室温で2時間乾燥後、1%スキムミルク(Difco社製)−0.1%ツィーン20−PBSに10分浸漬しマスキングを行った。その後、充分に乾燥した。
(2)着色ラテックス粒子標識抗体の作製
赤色ラテックス粒子分散液(PL−Latex、10%、粒子径450nm、ポリマーラボトリーズ社製)100μLを、10000rpm、5分間遠心分離を行った。沈渣に抗Hpモノクローナル抗体82A3溶液(1mg/ml)1ml加え、充分混和して、室温、1時間反応を行った。未反応のモノクローナル抗体を除去するため、10000rpm、5分間遠心分離を行い、沈渣をPBS1mlに懸濁し、再度遠心分離を行った。1%スキムミルク1mlを加え、室温、1時間反応させてマスキングを行った。その後、10000rpm、5分間遠心分離を行い、1%スキムミルク−0.01%アジ化ナトリウムを含むPBS1mlに沈渣を懸濁した。
(3)着色ラテックス標識物保持担体の作製
5mm×10mmに裁断したグラスフィルターを、1%濃度に調製したスキムミルクに5分間浸漬し、ブロッキングを行った。室温、2時間乾燥後、(2)で作製した着色ラテックス粒子標識抗体を10μL塗布した。その後、充分に乾燥し着色ラテックス標識物保持担体とした。
(4)イムノクロマトグラフィー試験片の作製
(1)で作製したそれぞれの抗体固相化支持体の下端から2mmの位置まで(3)で作製した着色ラテックス標識物保持担体を重ねた。更に、着色ラテックス標識物保持担体上に液体試料吸収用担体としてDE81(ワットマン社製)を下端から2.5mmの位置まで重ねた。また、抗体固相化支持体の上端から2mmの位置まで吸水性担体(3MM Chr、ワットマン社製)を重ね、最後に透明なテープを上部に貼り固定してイムノクロマトグラフィー試験片とした。
(5)Hp抗原標準液の測定
0.5%BSA−0.02%ツィーン20を含む150mMホウ酸ナトリウム緩衝液(pH8)で希釈したHp抗原標準液50μLを上記で得られたイムノクロマトグラフィー試験片の液体試料吸収用担体部に滴下して展開させ、10分後に目視判定をした。その結果を表8に示す。「+」はテストラインの赤いラインを確認できること、「±」はテストラインの赤い色が確認できるが非常に色が薄いこと、「−」はテストラインの赤いラインを確認できないことを示す。酢酸アンモニウム緩衝液(pH4)を用いてテストラインを固相化することで、Hp抗原濃度0.5μg/mlまで正確に判定可能であった。
(実施例9)イムノクロマトグラフィーによる糞便検体中Hpの検出
尿素呼気試験によりHp陽性者及び陰性者と判定された各10名の糞便検体50mgを実施例4で示した150mMホウ酸ナトリウム(pH8)を用いる便懸濁用緩衝液1mLに懸濁した。便懸濁液50μLを、実施例3(液体試料吸収用担体としてDE81を使用)、実施例5、実施例6、実施例7(実施例8で作製した各イムノクロマトグラフィー試験片の液体試料吸収用担体に滴下した。10分後にテストラインの赤いラインの有無を目視判定した。その結果、いずれの試験片においても、陽性検体では、全10例とも赤いラインが確認でき、陽性と判定された。一方、陰性検体では、全10例とも赤いラインは確認できず、陰性と判定された。なお、コントロールラインは全検体で確認できた。これらの検体をメリディアン社製のHpSA ELISA(ポリクローナル抗体を使用した糞便中Hp抗原検出酵素免疫測定キット)を用いて、添付文書に従って試験した結果、陽性検体は全て陽性と判定された。しかし、陰性検体10例の内、2例は陽性と判定され、偽陽性率が20%であった。
実施例10 イムノクロマトグラフィーによる糞便検体中Hpの検出
尿素呼気試験により判定されたHp陽性者66名及び陰性者12名の糞便検体50mgを実施例4で示したPBSを用いる便懸濁用緩衝液1mLに懸濁した。便懸濁液50μLを、実施例3で作製したイムノクロマトグラフィー試験片(液体試料吸収用担体としてDE81を使用)の液体試料吸収用担体に滴下した。10分後にテストラインの赤いラインの有無を目視判定した。その結果、陽性検体全66例とも赤いラインが確認でき、陽性と判定された。一方、陰性検体では、全12例とも赤いラインは確認できず、陰性と判定され、一致率100%であった。なお、コントロールラインは全検体で確認できた。
実施例11 臨床分離Hp株に対する反応性の検討
臨床から分離したHp株120株に対する反応性を検討した。実施例1に記載したのと同様の方法により各菌株を培養して菌体を集め、菌体を超音波処理することでHp抗原を調製した。0.5%BSA−0.02%ツィーン20を含む150mMホウ酸ナトリウム緩衝液(pH8)で0.25μg/mLに希釈したHp抗原液50μLを実施例3で作製したイムノクロマトグラフィー試験片(液体試料吸収用担体としてDE81を使用)の液体試料吸収用担体に滴下した。10分後にテストラインの赤いラインの有無を目視判定した。その結果、臨床分離Hp株全120株とも赤いラインを確認でき、陽性と判定した。なお、コントロールラインは全検体で確認できた。
実施例12 他の菌株に対する反応性
Helicobacter hepaticus ATCC51448株、Helicobacter felis ATCC49179株、Helicobacter mustelae ATCC43772株、Helicobacter cinaedi ATCC35683株、Escherichia coli ATCC25922株、Campylobacter jejuni ATCC29428株、Bacteroides vulgatus IFO14291株、Bifidobacterium infantis JCM1222株およびBifidobacterium breve JCM1192株に対する反応性を検討した。菌体を超音波処理することで菌体破砕物を得た。0.5%BSA−0.02%ツィーン20を含む150mMホウ酸ナトリウム緩衝液(pH8)でタンパク質濃度10μg/mLに希釈した各菌体破砕物50μLを実施例3で作製したイムノクロマトグラフィー試験片(液体試料吸収用担体としてDE81を使用)の液体試料吸収用担体に滴下した。10分後にテストラインの赤いラインの有無を目視判定した。その結果、全ての菌株で赤いラインを確認せず、陰性と判定した。なお、コントロールラインは全検体で確認できた。
産業上の利用可能性
本発明は、上述の構成よりなるので、糞便を検体として用い、感度よくヘリコバクター・ピロリへの感染を判定することができるイムノクロマトグラフィー試験片及び診断キットを提供することができる。Technical field
The present invention relates to an immunochromatographic test strip and a diagnostic kit.
Background art
Helicobacter pylori is a bacterium found in human gastric mucosa. Helicobacter pylori infection rates are closely related to socio-economic conditions, with developing countries having higher infection rates and developed countries tending to have lower infection rates. Among them, it is remarkably high, and it is said that 80% of people are over 40 years old. In recent years, it has become clear that Helicobacter pylori can cause various gastric and duodenal diseases such as gastric ulcer, duodenal ulcer, chronic gastritis, and even gastric cancer.
Since it has become clear that eradication of Helicobacter pylori can reduce the possibility of suffering from these diseases, international discussions have been conducted on diseases that are eradicated by Helicobacter pylori, and now there are gastric ulcers and duodenal ulcers. Gastric malignant lymphoma, stomach after resection of early gastric cancer, etc. are recognized as applicable diseases for sterilization.
As Helicobacter pylori eradication therapy has been recognized as a new treatment for stomach and duodenal diseases, clinical guidelines have been created by the Japanese Society of Gastroenterology, and the presence diagnosis and eradication determination method for Helicobacter pylori infection (Journal of Japanese Society of Gastroenterology, 96, 199-207, 1999). In the above clinical trial guideline, the presence diagnosis is performed by culturing, microscopic examination, and urease test of gastric biopsy tissue, which is an invasive examination method, and sterilization is determined by culture, microscopic examination and noninvasive examination of gastric biopsy tissue. The method has been shown to require the urea breath test. Moreover, it has been shown that in a special case such as when the subject is a child, the determination is performed by using a combination of blood anti-Helicobacter pylori antibody test and presence diagnosis.
However, these methods for testing for Helicobacter pylori infection have the following problems. In the invasive examination method, the subject is forced to suffer a great deal of pain by inserting a gastroscope and performing a biopsy. Non-invasive testing greatly improves the suffering of subjects, but urea breath testing requires fasting before testing. In addition, the urea breath test requires a device such as a mass spectrum or an infrared spectrophotometer, and can be performed only at a specific facility, resulting in a high cost. The antibody test is not suitable for sterilization determination because the antibody titer in blood remains high for a long time even after sterilization. Therefore, there is a demand for an inspection method that can directly and specifically detect Helicobacter pylori infection in place of these inspections.
Conventionally, separation culture using a selective medium for infectious bacteria from gastrointestinal excrement, particularly feces, has been carried out as a direct inspection method for intestinal bacteria. However, despite many attempts on Helicobacter pylori, there have been few reports isolated from feces. The reason for this is that Helicobacter pylori is in vitro, and when the environmental conditions worsen such as low temperature, nutrient deficiency, oxygen deficiency, etc., the shape changes from normal spiral bodies to non-culturable spheroids. It can be considered that the spheroids that cannot be separated and cultured are also changed.
On the other hand, regarding the direct detection of Helicobacter pylori from feces by an immunological method based on antigen-antibody reaction, there is a method for detecting Helicobacter pylori in fecal samples such as feces by immunoassay using polyclonal antibodies against Helicobacter pylori. (J. Clin. Microbiol., 33, 2162-2165, 1995, JP 10-10128 (Patent No. 3043999)).
However, since polyclonal antibodies generally have cross-reactivity and are less specific and have the disadvantage that antibody titers and specificities vary from lot to lot of antiserum, the production of diagnostic agents using polyclonal antibodies is essential. In particular, there is a problem that quality control is difficult. In reality, the appearance of false negatives and low specificity are problematic for the fecal Helicobacter pylori antigen detection kit “HpSA” using a polyclonal antibody manufactured by Meridian, the patent holder of Patent No. 3043999. (Medical Tribune, 4-5, June 3, 1999 issue; Am. J. Gastroenterol., 94, 1830-1833, 1999).
Summary of invention
An object of the present invention is to provide an immunochromatographic test piece and a diagnostic kit that can detect susceptibility to Helicobacter pylori with high sensitivity using stool as a specimen.
In the present invention, a colored latex label holding carrier and a liquid sample absorbing carrier comprising a filter paper are laminated in order from the bottom on the lower end of a strip-shaped antibody-immobilized support, whereas the antibody-immobilized support An immunochromatographic test piece comprising a laminate in which a water-absorbing carrier made of filter paper is laminated on the upper end of the antibody, wherein the antibody-immobilized support is a Helicobacter pylori native catalase and antigen on a nitrocellulose sheet. The colored latex particle label holding carrier is a colored latex in which a monoclonal antibody that performs an antigen-antibody reaction with Helicobacter pylori native catalase is immobilized on a colored latex particle. Immunochromatography in which non-woven fabric is impregnated with particle-labeled anti-Helicobacter pylori antibody It is a fee test piece.
Detailed Disclosure of the Invention
The present invention is described in detail below.
In the immunochromatographic test piece of the present invention, a colored latex label holding carrier and a liquid sample absorbing carrier consisting of filter paper are laminated in order from the bottom on the lower end of a strip-shaped antibody-immobilized support, while the antibody It consists of a laminate in which a water-absorbing carrier made of filter paper is laminated on the upper end of the solid support.
The antibody-immobilized support is a nitrocellulose sheet on which a monoclonal antibody (hereinafter also referred to as an anti-Hp monoclonal antibody) that undergoes an antigen-antibody reaction with Helicobacter pylori native catalase is immobilized.
Examples of the anti-Hp monoclonal antibody include hybridoma 21G2 (FERM BP-7336), 41A5 (FERM BP-7337), 82B9 (FERM BP-7338), 31A3 (FERM P-18329), or 82A3 (FERM Mention may be made of the monoclonal antibodies produced from P-18328).
The solid-phased anti-Hp monoclonal antibody recognizes Helicobacter pylori catalase in the specimen and can capture a complex of catalase and a colored latex particle-labeled anti-Helicobacter pylori antibody. Therefore, if the anti-Hp monoclonal antibody is immobilized on a line on an antibody-immobilized support, the line is lifted by colored latex particles.
The antibody-immobilized support can be obtained by applying a buffer solution in which an anti-Hp monoclonal antibody is dispersed to a nitrocellulose sheet and drying.
Although it does not specifically limit as said buffer solution, From the point of the detection sensitivity of Helicobacter pylori of the obtained immunochromatography test piece, a sodium acetate buffer solution, an ammonium acetate buffer solution, a sodium phosphate buffer solution etc. are preferable.
The antibody-immobilized support may be further immobilized with an antibody against an anti-Hp monoclonal antibody, a Helicobacter pylori catalase, or a substance that specifically binds to a colored latex particle label for a control line. Good. Thereby, it can be determined whether the immunochromatography test was performed normally.
The colored latex particle-labeled carrier holding carrier is impregnated with a colored latex particle-labeled anti-Helicobacter pylori antibody by immobilizing a monoclonal antibody that performs antigen-antibody reaction with Helicobacter pylori native catalase on the colored latex particle. Is.
The nonwoven fabric is not particularly limited, and examples thereof include those made of polyester, rayon, polypropylene, cellulose, pulp and the like.
The latex particles are not particularly limited. For example, homopolymers and copolymers of vinyl monomers such as styrene, vinyl chloride, acrylonitrile, vinyl acetate, acrylic acid ester, and methacrylic acid ester; styrene-butadiene copolymer, Examples thereof include fine particles formed by coloring a butadiene copolymer such as a methyl methacrylate-butadiene copolymer. Among these, polystyrene-based latex particles are preferably used because they have excellent antibody or antigen adsorptivity and can maintain biological activity stably for a long period of time.
The method for supporting the anti-Hp monoclonal antibody on the colored latex particles is not particularly limited, and can be carried out, for example, by a physical or chemical adsorption method.
The colored latex particle label holding carrier may be further impregnated with a second colored latex particle label in which an antibody or the like is fixed to a colored latex colored in a different color. Such a second colored latex particle label can be used as a control line marker.
It is preferable that the colored latex particle label holding carrier is blocked with skim milk or bovine serum albumin. Thereby, a nonspecific reaction can be suppressed and the false positive which determines a negative sample as positive can be eliminated.
The liquid sample absorption carrier preferably has an acidic substance adsorption ability. Pigments and impurities in stool are rich in acidic substances. By maintaining the acidic substance adsorption ability, it is possible to express excellent detection sensitivity and specificity for Helicobacter pylori. A commercially available product can be used as the liquid sample absorbing carrier having such an acidic substance adsorption ability, and examples thereof include DE81 (manufactured by Whatman).
The immunochromatographic test piece of the present invention may be further fixed to a substrate made of plastic or the like to give strength, or a transparent tape or the like may be attached to the surface for protection.
It does not specifically limit as a manufacturing method of the immunochromatography test piece of this invention, For example, it can obtain by the following method.
(1) Preparation of antibody-immobilized support
In order to produce an antibody-immobilized support in which anti-Hp monoclonal antibody and anti-rabbit IgG antibody were linearly immobilized, a nitrocellulose sheet (manufactured by Whatman) was cut into 5 mm × 20 mm, and 10 mm from the lower end thereof. A solution of monoclonal antibody 21G2 was applied at the position, and a solution of anti-rabbit IgG goat polyclonal antibody (manufactured by Cappel) was applied at a position of 15 mm using Biojet Q3000 (manufactured by Biodot). After drying at room temperature for 2 hours, masking was performed by immersing in 1% skim milk (Difco) -0.1% Tween 20-PBS for 10 minutes. Then, it fully dried.
(2) Preparation of colored latex particle label holding carrier
a. Red latex particle labeled anti-Helicobacter pylori antibody
1.2 mL of PBS was added to 300 μL of red latex particle dispersion (PL-Latex, 10%, 450 nm, manufactured by Polymer Laboratories), and centrifuged at 13,000 rpm for 5 minutes. To the precipitate, 1.5 mL of a monoclonal antibody 21G2 solution (5 mg / mL) was added, mixed well, and reacted at room temperature for 1 hour. In order to remove the unreacted monoclonal antibody, centrifugation was performed at 13,000 rpm for 5 minutes, the precipitate was suspended in 1.5 mL of PBS, and centrifuged again. Masking was performed by adding 1 mL of 1% skim milk and reacting at room temperature for 1 hour. Thereafter, centrifugation was performed at 13,000 rpm for 5 minutes, and the sediment was suspended in 1.5 mL of PBS containing 1% skim milk-0.01% sodium azide.
b. Blue latex particle labeled rabbit IgG
Blue latex particle-labeled rabbit IgG was treated in the same manner as described above using a blue latex particle dispersion (PL-Latex, 10%, 450 nm, manufactured by Polymer Laboratories) and rabbit IgG (0.5 mg / mL, manufactured by Cappel). Prepared.
c. Colored latex particle label holding carrier
Equal amounts of the above-mentioned two kinds of colored latex particle-labeled antibodies were mixed, impregnated with 10 μL of 5 mm × 5 mm Benlyse (registered trademark) nonwoven fabric (manufactured by Asahi Kasei Co., Ltd.), and dried by ventilation.
(3) Preparation of immunochromatographic test piece
A colored latex label holding carrier was stacked from the lower end of the antibody-immobilized support to a position of 2.5 mm. Further, a liquid sample absorbing carrier (3MM Chr, manufactured by Whatman) was stacked on the colored latex label holding carrier from the lower end to a position of 2.5 mm. In addition, a water-absorbing carrier (3MM Chr, manufactured by Whatman Co., Ltd.) was stacked up to a position 2 mm from the upper end of the antibody-immobilized support, and finally a transparent tape was pasted and fixed to obtain an immunochromatographic test piece.
A diagnostic kit including the immunochromatographic test strip of the present invention is also one aspect of the present invention.
In addition to the immunochromatographic test strip of the present invention, the diagnostic kit may contain, for example, wells, positive controls, negative controls, stool suspension buffers, concentrated washing solutions, and the like.
The stool suspension buffer is not particularly limited, but PBS and / or sodium borate buffer is preferable from the viewpoint of excellent detection sensitivity.
BEST MODE FOR CARRYING OUT THE INVENTION
Hereinafter, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to these examples.
(Example 1) Examination of antibody immobilization buffer
(1) Preparation of antibody-immobilized support
10 mM each buffer solution containing 3% methanol (sodium phosphate (pH 5-8), sodium acetate (pH 4-6), ammonium acetate (pH 4-6), sodium citrate (pH 4-6), Tris-HCl (pH 7-6) 9), sodium borate (pH 8 to 10), ammonium chloride (pH 8 to 11), ammonium carbonate (pH 8 to 10)) were prepared, and anti-Helicobacter pylori (Hp) monoclonal antibody 21G2 was added to a concentration of 1 mg / mL did. A nitrocellulose sheet (manufactured by Whatman) is cut to 5 mm × 20 mm, and the anti-Hp monoclonal antibody 21G2 solution prepared with each buffer solution for the test line is placed 10 mm from the lower end of the nitrocellulose sheet, and the anti-Hp monoclonal antibody 21G2 solution is used for the control line. A mouse IgG polyclonal antibody (manufactured by Cappel) (1 mg / mL) was applied in a linear form using Biojet Q3000 (manufactured by Biodot) and solidified. After drying at room temperature for 2 hours, masking was performed by immersing in 1% skim milk (Difco) -0.1% Tween 20-PBS for 10 minutes. Then, it fully dried.
(2) Preparation of colored latex particle labeled antibody
100 μL of red latex particle dispersion (PL-Latex, 10%, particle diameter 450 nm, manufactured by Polymer Laboratories) was centrifuged at 10,000 rpm for 5 minutes. 1 mL of anti-Hp monoclonal antibody 21G2 solution (1 mg / mL) was added to the precipitate, mixed well, and reacted at room temperature for 1 hour. In order to remove the unreacted monoclonal antibody, centrifugation was performed at 10,000 rpm for 5 minutes, the precipitate was suspended in 1 mL of PBS, and centrifuged again. Masking was performed by adding 1 mL of 1% skim milk and reacting at room temperature for 1 hour. Thereafter, centrifugation was performed at 10,000 rpm for 5 minutes, and the precipitate was suspended in 1 mL of PBS containing 1% skim milk-0.01% sodium azide.
(3) Preparation of immunochromatographic test piece
A glass filter (manufactured by Whatman) cut to 5 mm × 10 mm from the lower end of each antibody-immobilized support prepared in (1) to a position of 2 mm was stacked. Further, a liquid sample absorbing carrier (C / P-30, manufactured by Whatman) was stacked on the glass filter from the lower end to a position of 2.5 mm. In addition, a water-absorbing carrier (3MM Chr, manufactured by Whatman Co., Ltd.) was stacked up to a position 2 mm from the upper end of the antibody-immobilized support, and finally a transparent tape was pasted and fixed to obtain an immunochromatographic test piece.
(4) Preparation of Hp standard antigen
Helicobacter pylori ATCC43504 strain was microaerobically cultured at 37 ° C. for 4 days on 150 brain heart infusion agar medium (Difco) containing 5% horse defibrillated blood. After culturing, the cells were collected, suspended in 40 mL of PBS, and centrifuged at 3000 rpm for 20 minutes. The sediment was suspended in 40 mL of PBS containing 0.5% formalin and inactivated by standing at 4 ° C. overnight. The inactivated cells were washed 3 times with 40 mL of PBS to remove formalin, and then resuspended in the same amount of PBS. After confirming the turbidity (absorbance at 540 nm) and the total number of bacteria (microscopic observation using a calculation board) of the bacterial solution, the cells were crushed by ultrasonic treatment. The disrupted cells were centrifuged at 3000 rpm for 20 minutes, and the supernatant was further ultracentrifuged at 30000 rpm for 30 minutes. This supernatant was filtered through a 0.2 μm filter to obtain an Hp standard antigen.
(5) Measurement of Hp antigen standard solution
It was obtained in (3) by mixing 50 μL of Hp antigen standard solution diluted with 0.5% BSA-0.02% Tween 20-PBS and 10 μL of colored latex particle-labeled antibody solution prepared in (2). The carrier portion for absorbing the liquid sample of the immunochromatographic test piece was immersed and developed, and visually judged after 10 minutes. The results are shown in Table 1. “+” Indicates that the red line of the test line can be confirmed, “±” indicates that the red color of the test line can be confirmed but the color is very light, and “−” indicates that the red line of the test line cannot be confirmed. By immobilizing the test line using sodium acetate buffer (pH 5) and ammonium acetate buffer (pH 5), it was possible to determine the Hp antigen standard solution to 0.5 μg / mL.
(Example 2) Comparison of blocking solutions of colored latex label holding carrier
(1) Preparation of antibody-immobilized support
A nitrocellulose sheet (manufactured by Whatman) was cut into 5 mm × 20 mm, and an anti-Hp monoclonal antibody solution (1 mg) prepared with 10 mM ammonium acetate (pH 5) buffer containing 3% methanol for test line at a position 10 mm from the lower end. / Ml) was applied to a 15 mm position as a control line for anti-mouse IgG polyclonal antibody (manufactured by Cappel) (1 mg / mL) linearly using BioJet Q3000 (manufactured by Biodot) and solidified. . After drying at room temperature for 2 hours, masking was performed by immersing in 1% skim milk (Difco) -0.1% Tween 20-PBS for 10 minutes. Then, it fully dried.
(2) Comparison of blocking solutions when preparing colored latex label holding carrier
Polyvinyl alcohol (hereinafter referred to as PVA, manufactured by Wako Pure Chemical Industries, Ltd.), polyvinylpyrrolidone K15 (hereinafter referred to as PVP, manufactured by Tokyo Chemical Industry Co., Ltd.), Tween 20, Triton X-100, sodium dodecyl sulfate (hereinafter referred to as SDS), skim milk, Using bovine serum albumin (hereinafter referred to as BSA), the effect on blocking of a glass fiber filter, which is a carrier for holding a colored latex label, was examined. The glass filter cut into 5 mm × 10 mm was immersed for 5 minutes in PVA, PVP, Tween 20, Triton X-100, SDS, skim milk, and BSA prepared to a concentration of 1% for blocking. After drying at room temperature for 2 hours, 10 μL of the colored latex particle-labeled antibody prepared in Example 1 was applied. Thereafter, it was sufficiently dried to obtain a colored latex label holding carrier.
(3) Preparation of immunochromatographic test piece
Each colored latex labeled antibody holding carrier prepared in (2) was stacked from the lower end of the antibody-immobilized support prepared in (1) to a position of 2 mm. Further, a liquid sample absorbing carrier (C / P-30, manufactured by Whatman) was stacked on the colored latex holding carrier from the lower end to a position of 2.5 mm. In addition, a water-absorbing carrier (3MM Chr, manufactured by Whatman Co., Ltd.) was stacked up to a position 2 mm from the upper end of the antibody-immobilized support, and finally a transparent tape was pasted and fixed to obtain an immunochromatographic test piece.
(4) Detection of Helicobacter pylori in stool samples
A stool specimen (0.1 g) of 5 Hp-positive and 5 Hp-negative was suspended in 2 mL of 0.5% BSA-0.02% Tween 20-PBS. Centrifugation was performed at 3000 rpm for 1 minute to remove impurities, and 50 μL of the supernatant was dropped onto the liquid sample absorption carrier part of the immunochromatography test piece prepared in (4). Visual judgment was made after 10 minutes. The results are shown in Table 2. “+” Indicates that the red line of the test line can be confirmed, “±” indicates that the red color of the test line can be confirmed, but the color is very light, “−” indicates that the red line of the test line cannot be confirmed, “*” Indicates that latex labeled antibody aggregates and cannot be developed to the test line. The glass fiber filter blocked with BSA or skim milk could be determined to be positive in all cases for positive samples and negative in all cases for negative samples.
(Example 3) Comparison of liquid sample absorption carriers
(1) Production of colored latex label holding carrier
The glass filter cut into 5 mm × 10 mm was immersed in skim milk prepared at 1% concentration for 5 minutes for blocking. After drying at room temperature for 2 hours, 10 μL of the colored latex particle-labeled antibody prepared in Example 1 was applied. Thereafter, it was sufficiently dried to obtain a colored latex label holding carrier.
(2) Comparison of liquid sample absorption carriers
The colored latex label holding carrier prepared in (1) was stacked from the lower end of the antibody-immobilized support prepared in Example 2 to a position of 2 mm. Furthermore, C / P-30 (manufactured by Whatman), P81 (manufactured by Whatman), C / DE30 (manufactured by Whatman), DE81 (manufactured by Whatman), as a carrier for absorbing a liquid sample on the colored latex label holding carrier, GF / QA30 (manufactured by Whatman) was stacked from the lower end to a position of 2.5 mm. In addition, a water-absorbing carrier (3MM Chr, manufactured by Whatman Co., Ltd.) was stacked up to a position 2 mm from the upper end of the antibody-immobilized support, and finally a transparent tape was pasted and fixed to obtain an immunochromatographic test piece.
(3) Measurement of Hp antigen standard solution
50 μL of Hp antigen standard solution diluted with 0.5% BSA-0.02% Tween 20-PBS is dropped onto the liquid sample absorption carrier part of the immunochromatographic test piece obtained above, and developed after 10 minutes. I made a decision. The results are shown in Table 3. “+” Indicates that the red line of the test line can be confirmed, “±” indicates that the red color of the test line can be confirmed but the color is very light, and “−” indicates that the red line of the test line cannot be confirmed. When DE81 was used as the carrier for absorbing the liquid sample, it was possible to determine the Hp antigen concentration to 0.1 μg / mL.
(Example 4) Effect of composition of stool suspension buffer on Hp detection
(1) Preparation of immunochromatographic test piece
The colored latex label holding carrier prepared in Example 3 was stacked from the lower end of the antibody-immobilized support prepared in Example 2 to a position of 2 mm. Further, DE81 (manufactured by Whatman) as a liquid sample absorbing carrier was stacked on the colored latex label holding carrier to a position 2.5 mm from the lower end. In addition, a water-absorbing carrier (3MM Chr, manufactured by Whatman Co., Ltd.) was stacked up to a position 2 mm from the upper end of the antibody-immobilized support, and finally a transparent tape was pasted and fixed to obtain an immunochromatographic test piece.
(2) Effect of composition of stool suspension buffer on Hp standard antigen detection
150 mM each buffer solution (sodium phosphate (pH 5-8), sodium borate (pH 8-8) containing 0.5% BSA-0.02% Tween 20-PBS and 0.5% BSA-0.02% Tween 20) 50 μL of the Hp antigen standard solution diluted in 10)) was dropped onto the liquid sample absorption carrier part of the immunochromatographic test piece obtained above, and developed, and visually judged after 10 minutes. The results are shown in Table 4. “+” Indicates that the red line of the test line can be confirmed, “±” indicates that the red color of the test line can be confirmed but the color is very light, and “−” indicates that the red line of the test line cannot be confirmed. When PBS and sodium borate buffer were used as the stool suspension buffer, it was possible to accurately determine the Hp antigen concentration to 0.1 μg / mL.
(Example 5) Preparation of immunochromatographic test piece using anti-Hp monoclonal antibody 82B9
(1) Preparation of antibody-immobilized support
10 mM each buffer solution containing 3% methanol (sodium phosphate (pH 5-8), ammonium acetate (pH 4-6), sodium borate (pH 8-10)) was prepared and anti-Helicobacter pylori (Hp) monoclonal antibody 82B9 was added to a concentration of 1 mg / mL. A nitrocellulose sheet (manufactured by Whatman) is cut to 5 mm × 20 mm, and an anti-Hp monoclonal antibody 82B9 solution prepared with each buffer solution for the test line is placed at a position 10 mm from the lower end of the nitrocellulose sheet. A mouse IgG polyclonal antibody (manufactured by Cappel) (1 mg / mL) was applied in a linear form using Biojet Q3000 (manufactured by Biodot) and solidified. After drying at room temperature for 2 hours, masking was performed by immersing in 1% skim milk (Difco) -0.1% Tween 20-PBS for 10 minutes. Then, it fully dried.
(2) Preparation of colored latex particle labeled antibody
100 μL of red latex particle dispersion (PL-Latex, 10%, particle diameter 450 nm, manufactured by Polymer Laboratories) was centrifuged at 10,000 rpm for 5 minutes. 1 mL of anti-Hp monoclonal antibody 82B9 solution (1 mg / mL) was added to the precipitate, mixed well, and reacted at room temperature for 1 hour. In order to remove the unreacted monoclonal antibody, centrifugation was performed at 10,000 rpm for 5 minutes, the precipitate was suspended in 1 mL of PBS, and centrifuged again. Masking was performed by adding 1 mL of 1% skim milk and reacting at room temperature for 1 hour. Thereafter, centrifugation was performed at 10,000 rpm for 5 minutes, and the precipitate was suspended in 1 mL of PBS containing 1% skim milk-0.01% sodium azide.
(3) Production of colored latex label holding carrier
The glass filter cut into 5 mm × 10 mm was immersed in skim milk prepared at 1% concentration for 5 minutes for blocking. After drying at room temperature for 2 hours, 10 μL of the colored latex particle-labeled antibody prepared in (2) was applied. Thereafter, it was sufficiently dried to obtain a colored latex label holding carrier.
(4) Preparation of immunochromatographic test piece
The colored latex label holding carrier prepared in (3) was stacked from the lower end of each antibody-immobilized support prepared in (1) to a position of 2 mm. Further, DE81 (manufactured by Whatman) as a liquid sample absorbing carrier was stacked on the colored latex label holding carrier to a position 2.5 mm from the lower end. In addition, a water-absorbing carrier (3MM Chr, manufactured by Whatman Co., Ltd.) was stacked up to a position 2 mm from the upper end of the antibody-immobilized support, and finally a transparent tape was pasted and fixed to obtain an immunochromatographic test piece.
(5) Measurement of Hp antigen standard solution
50 μL of Hp antigen standard solution diluted with 150 mM sodium borate buffer (pH 8) containing 0.5% BSA-0.02% Tween 20 is dropped onto the liquid sample absorption carrier part of the immunochromatographic test piece obtained above. The film was developed and visually judged after 10 minutes. The results are shown in Table 5. “+” Indicates that the red line of the test line can be confirmed, “±” indicates that the red color of the test line can be confirmed but the color is very light, and “−” indicates that the red line of the test line cannot be confirmed. By immobilizing the test line using sodium phosphate buffer (pH 6), it was possible to accurately determine the Hp antigen concentration to 0.25 μg / mL.
(Example 6) Preparation of immunochromatographic test piece using anti-Hp monoclonal antibody 41A5
(1) Preparation of antibody-immobilized support
10 mM each buffer solution containing 3% methanol (sodium phosphate (pH 5-8), ammonium acetate (pH 4-6), sodium borate (pH 8-10)) was prepared and anti-Helicobacter pylori (Hp) monoclonal antibody 41A5 was added to a concentration of 1 mg / mL. A nitrocellulose sheet (manufactured by Whatman) is cut into 5 mm × 20 mm, and an anti-Hp monoclonal antibody 41A5 solution prepared with each buffer solution for test lines is placed at a position 10 mm from the lower end of the nitrocellulose sheet. A mouse IgG polyclonal antibody (manufactured by Cappel) (1 mg / mL) was applied in a linear manner using Biojet Q3000 (manufactured by Biodot) and solidified. After drying at room temperature for 2 hours, masking was performed by immersing in 1% skim milk (Difco) -0.1% Tween 20-PBS for 10 minutes. Then, it fully dried.
(2) Preparation of colored latex particle labeled antibody
100 μL of red latex particle dispersion (PL-Latex, 10%, particle diameter 450 nm, manufactured by Polymer Laboratories) was centrifuged at 10,000 rpm for 5 minutes. 1 mL of anti-Hp monoclonal antibody 41A5 solution (1 mg / mL) was added to the precipitate, mixed well, and reacted at room temperature for 1 hour. In order to remove the unreacted monoclonal antibody, centrifugation was performed at 10,000 rpm for 5 minutes, the precipitate was suspended in 1 mL of PBS, and centrifuged again. Masking was performed by adding 1 mL of 1% skim milk and reacting at room temperature for 1 hour. Thereafter, centrifugation was performed at 10,000 rpm for 5 minutes, and the precipitate was suspended in 1 mL of PBS containing 1% skim milk-0.01% sodium azide.
(3) Production of colored latex label holding carrier
The glass filter cut into 5 mm × 10 mm was immersed in skim milk prepared at 1% concentration for 5 minutes for blocking. After drying at room temperature for 2 hours, 10 μL of the colored latex particle-labeled antibody prepared in (2) was applied. Thereafter, it was sufficiently dried to obtain a colored latex label holding carrier.
(4) Preparation of immunochromatographic test piece
The colored latex label holding carrier prepared in (3) was stacked from the lower end of each antibody-immobilized support prepared in (1) to a position of 2 mm. Further, DE81 (manufactured by Whatman) as a liquid sample absorbing carrier was stacked on the colored latex label holding carrier to a position 2.5 mm from the lower end. In addition, a water-absorbing carrier (3MM Chr, manufactured by Whatman Co., Ltd.) was stacked up to a position 2 mm from the upper end of the antibody-immobilized support, and finally a transparent tape was pasted and fixed to obtain an immunochromatographic test piece.
(5) Measurement of Hp antigen standard solution
50 μL of Hp antigen standard solution diluted with 150 mM sodium borate buffer (pH 8) containing 0.5% BSA-0.02% Tween 20 is dropped onto the liquid sample absorption carrier part of the immunochromatographic test piece obtained above. The film was developed and visually judged after 10 minutes. The results are shown in Table 5. “+” Indicates that the red line of the test line can be confirmed, and “−” indicates that the red line of the test line cannot be confirmed. By immobilizing the test line using ammonium acetate buffer (pH 4 and pH 5), it was possible to accurately determine the Hp antigen concentration to 0.25 μg / mL.
(Example 7) Preparation of immunochromatographic test piece using anti-Hp monoclonal antibody 31A3 and antibody 21G2
(1) Preparation of antibody-immobilized support
10 mM each buffer solution containing 3% methanol (sodium phosphate (pH 5-8), ammonium acetate (pH 4-6), sodium borate (pH 8-10)) was prepared and anti-Helicobacter pylori (Hp) monoclonal antibody 31A3 was added to a concentration of 1 mg / ml. A nitrocellulose sheet (manufactured by Whatman) is cut into 5 mm × 20 mm, and an anti-Hp monoclonal antibody solution prepared with each buffer solution for test lines is placed at a position 10 mm from the lower end, and an anti-mouse is used as a control line at a position 15 mm. An IgG polyclonal antibody (manufactured by Cappel) (1 mg / ml) was applied in a linear form using Biojet Q3000 (manufactured by Biodot) and solidified. After drying at room temperature for 2 hours, masking was performed by immersing in 1% skim milk (Difco) -0.1% Tween 20-PBS for 10 minutes. Then, it fully dried.
(2) Preparation of immunochromatographic test piece
The antibody 21G2 colored latex label holding carrier prepared in Example 3 (1) was overlapped from the lower end of each antibody-immobilized support prepared in (1) to a position of 2 mm. Further, DE81 (manufactured by Whatman) as a liquid sample absorbing carrier was stacked on the colored latex label holding carrier to a position 2.5 mm from the lower end. In addition, a water-absorbing carrier (3MM Chr, manufactured by Whatman Co., Ltd.) was stacked up to a position 2 mm from the upper end of the antibody-immobilized support, and finally a transparent tape was pasted and fixed to obtain an immunochromatographic test piece.
(3) Measurement of Hp antigen standard solution
50 μL of Hp antigen standard solution diluted with 150 mM sodium borate buffer (pH 8) containing 0.5% BSA-0.02% Tween 20 is dropped onto the liquid sample absorption carrier part of the immunochromatographic test piece obtained above. The film was developed and visually judged after 10 minutes. The results are shown in Table 7. “+” Indicates that the red line of the test line can be confirmed, “±” indicates that the red color of the test line can be confirmed but the color is very light, and “−” indicates that the red line of the test line cannot be confirmed. By immobilizing the test line using sodium phosphate buffer (pH 7), it was possible to accurately determine the Hp antigen concentration to 0.25 μg / ml.
(Example 8) Preparation of immunochromatographic test piece using anti-Hp monoclonal antibody 82A3
(1) Preparation of antibody-immobilized support
10 mM each buffer solution containing 3% methanol (sodium phosphate (pH 5-8), ammonium acetate (pH 4-6), sodium borate (pH 8-10)) was prepared and anti-Helicobacter pylori (Hp) monoclonal antibody 82A3 was added to a concentration of 1 mg / ml. A nitrocellulose sheet (manufactured by Whatman) is cut into 5 mm × 20 mm, and an anti-Hp monoclonal antibody solution prepared with each buffer solution for test lines is placed at a position 10 mm from the lower end, and an anti-mouse is used as a control line at a position 15 mm. An IgG polyclonal antibody (manufactured by Cappel) (1 mg / ml) was applied in a linear form using Biojet Q3000 (manufactured by Biodot) and solidified. After drying at room temperature for 2 hours, masking was performed by immersing in 1% skim milk (Difco) -0.1% Tween 20-PBS for 10 minutes. Then, it fully dried.
(2) Preparation of colored latex particle labeled antibody
100 μL of red latex particle dispersion (PL-Latex, 10%, particle diameter 450 nm, manufactured by Polymer Laboratories) was centrifuged at 10,000 rpm for 5 minutes. 1 ml of the anti-Hp monoclonal antibody 82A3 solution (1 mg / ml) was added to the precipitate, mixed well, and reacted at room temperature for 1 hour. In order to remove the unreacted monoclonal antibody, centrifugation was performed at 10,000 rpm for 5 minutes, the precipitate was suspended in 1 ml of PBS, and centrifuged again. Masking was performed by adding 1 ml of 1% skim milk and reacting at room temperature for 1 hour. Thereafter, centrifugation was performed at 10,000 rpm for 5 minutes, and the precipitate was suspended in 1 ml of PBS containing 1% skim milk-0.01% sodium azide.
(3) Production of colored latex label holding carrier
The glass filter cut into 5 mm × 10 mm was immersed in skim milk prepared at 1% concentration for 5 minutes for blocking. After drying at room temperature for 2 hours, 10 μL of the colored latex particle-labeled antibody prepared in (2) was applied. Thereafter, it was sufficiently dried to obtain a colored latex label holding carrier.
(4) Preparation of immunochromatographic test piece
The colored latex label holding carrier prepared in (3) was stacked from the lower end of each antibody-immobilized support prepared in (1) to a position of 2 mm. Further, DE81 (manufactured by Whatman) as a liquid sample absorbing carrier was stacked on the colored latex label holding carrier to a position 2.5 mm from the lower end. In addition, a water-absorbing carrier (3MM Chr, manufactured by Whatman Co., Ltd.) was stacked up to a position 2 mm from the upper end of the antibody-immobilized support, and finally a transparent tape was pasted and fixed to obtain an immunochromatographic test piece.
(5) Measurement of Hp antigen standard solution
50 μL of Hp antigen standard solution diluted with 150 mM sodium borate buffer (pH 8) containing 0.5% BSA-0.02% Tween 20 is dropped onto the liquid sample absorption carrier part of the immunochromatographic test piece obtained above. The film was developed and visually judged after 10 minutes. The results are shown in Table 8. “+” Indicates that the red line of the test line can be confirmed, “±” indicates that the red color of the test line can be confirmed but the color is very light, and “−” indicates that the red line of the test line cannot be confirmed. By immobilizing the test line using ammonium acetate buffer (pH 4), it was possible to accurately determine the Hp antigen concentration to 0.5 μg / ml.
(Example 9) Detection of Hp in a stool specimen by immunochromatography
50 mg of each 10 stool specimens determined to be Hp positive and negative by the urea breath test were suspended in 1 mL of stool suspension buffer using 150 mM sodium borate (pH 8) shown in Example 4. 50 μL of the stool suspension was used for absorption of a liquid sample in each of the immunochromatographic test pieces prepared in Example 3 (using DE81 as a liquid sample absorption carrier), Example 5, Example 6, and Example 7 (Example 8). After 10 minutes, the presence or absence of a red line on the test line was visually determined, and as a result, in all the test specimens, a positive line could be confirmed in all 10 cases, and the test line was determined to be positive. On the other hand, in all of the negative samples, the red line was not confirmed in all 10 cases, and it was determined to be negative, and the control line was confirmed in all the samples. As a result of testing according to the package insert using the fecal Hp antigen detection enzyme immunoassay kit, all the positive samples were determined to be positive. Of 10 cases, 2 cases were judged as positive, false positive rate was 20%.
Example 10 Detection of Hp in stool specimens by immunochromatography
50 mg of fecal specimens of 66 Hp positive persons and 12 negative persons determined by the urea breath test were suspended in 1 mL of a stool suspension buffer using PBS shown in Example 4. 50 μL of stool suspension was dropped onto the liquid sample absorbing carrier of the immunochromatographic test piece prepared in Example 3 (using DE81 as the liquid sample absorbing carrier). After 10 minutes, the presence or absence of a red line on the test line was visually determined. As a result, a red line was confirmed in all 66 positive specimens, and it was determined to be positive. On the other hand, in the negative samples, no red line could be confirmed in all 12 cases, and it was determined to be negative and the coincidence rate was 100%. The control line was confirmed for all samples.
Example 11 Examination of reactivity to clinically isolated Hp strain
The reactivity to 120 Hp strains isolated from the clinic was examined. Each strain was cultured by the same method as described in Example 1 to collect microbial cells, and Hp antigen was prepared by sonicating the microbial cells. An immunochromatographic test piece (liquid sample) prepared in Example 3 using 50 μL of Hp antigen solution diluted to 0.25 μg / mL with 150 mM sodium borate buffer (pH 8) containing 0.5% BSA-0.02% Tween 20 The liquid sample was absorbed in a liquid sample absorption carrier (DE81 was used as an absorption carrier). After 10 minutes, the presence or absence of a red line on the test line was visually determined. As a result, all the 120 clinically isolated Hp strains could be confirmed as red lines and judged as positive. The control line was confirmed for all samples.
Example 12 Reactivity to other strains
Helicobacter hepaticus ATCC51448 strain, Helicobacter felis ATCC49179 strain, Helicobacter mustelae ATCC43772 strain, Helicobacter cinaedi ATCC35683 strain, Escherichia coli ATCC 25922 strain, Campylobacter jejuni ATCC29428 strain, Bacteroides vulgatus IFO14291 strain was examined for reactivity to Bifidobacterium infantis JCM1222 strain and Bifidobacterium breve JCM1192 strain . The microbial cell crushed material was obtained by ultrasonically treating the microbial cell. An immunochromatographic test piece prepared in Example 3 using 50 μL of each cell disruption diluted with 150 mM sodium borate buffer (pH 8) containing 0.5% BSA-0.02% Tween 20 to a protein concentration of 10 μg / mL ( The sample was dropped onto the liquid sample absorbing carrier (DE81 was used as the liquid sample absorbing carrier). After 10 minutes, the presence or absence of a red line on the test line was visually determined. As a result, the red line was not confirmed in all the strains, and it was determined to be negative. The control line was confirmed for all samples.
Industrial applicability
Since this invention consists of the above-mentioned structure, it can provide the immunochromatography test piece and diagnostic kit which can determine the infection to Helicobacter pylori with high sensitivity using feces as a test substance.
Claims (6)
前記抗体固相化支持体は、ニトロセルロースシート上に糞便検体中のヘリコバクター・ピロリのネイティブなカタラーゼと抗原抗体反応を行うモノクローナル抗体が固相化されてなり、
前記着色ラテックス粒子標識物保持担体は、着色ラテックス粒子にヘリコバクター・ピロリのネイティブなカタラーゼと抗原抗体反応を行うモノクローナル抗体を固定化してなる着色ラテックス粒子標識抗ヘリコバクター・ピロリ抗体が不織布に含浸されてなり、
ヘリコバクター・ピロリのネイティブなカタラーゼと抗原抗体反応を行うモノクローナル抗体は、ハイブリドーマ21G2(FERM BP−7336)、41A5(FERM BP−7337)、82B9(FERM BP−7338)、31A3(FERM P−18329)及び82A3(FERM P−18328)のいずれかより産生されるモノクローナル抗体からなる群より選択される少なくとも1つである
ことを特徴とするイムノクロマトグラフィー試験片。A colored latex label holding carrier is laminated on the lower end of the strip-shaped antibody solid phase support , and a liquid absorbing carrier made of filter paper is further laminated on the colored latex label holding carrier, while the antibody solid phase An immunochromatographic test piece comprising a laminate in which a water-absorbing carrier made of filter paper is laminated on the upper end of the fluorinated support ,
The antibody-immobilized support is formed by immobilizing a monoclonal antibody that performs an antigen-antibody reaction with a native catalase of Helicobacter pylori in a stool specimen on a nitrocellulose sheet,
The colored latex particle label holding carrier is formed by impregnating a non-woven fabric with colored latex particle-labeled anti-Helicobacter pylori antibody, in which colored latex particles are immobilized with Helicobacter pylori native catalase and a monoclonal antibody that performs an antigen-antibody reaction. ,
Monoclonal antibodies that undergo an antigen-antibody reaction with a native catalase of Helicobacter pylori include hybridomas 21G2 (FERM BP-7336), 41A5 (FERM BP-7337), 82B9 (FERM BP-7338), 31A3 (FERM P-18329) and An immunochromatographic test strip, which is at least one selected from the group consisting of monoclonal antibodies produced from any of 82A3 (FERM P-18328) .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001124885 | 2001-04-23 | ||
JP2001124885 | 2001-04-23 | ||
PCT/JP2002/004011 WO2002088737A1 (en) | 2001-04-23 | 2002-04-23 | Immunochromatographic test piece and diagnosis kit |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2002088737A1 JPWO2002088737A1 (en) | 2004-08-19 |
JP4443117B2 true JP4443117B2 (en) | 2010-03-31 |
Family
ID=18974193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002585986A Expired - Lifetime JP4443117B2 (en) | 2001-04-23 | 2002-04-23 | Immunochromatographic specimen and diagnostic kit |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP4443117B2 (en) |
WO (1) | WO2002088737A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106290855A (en) * | 2015-06-01 | 2017-01-04 | 上海凯创生物技术有限公司 | A kind of pylori antigen near-infrared fluorescent detection kit and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE454597B (en) * | 1984-04-02 | 1988-05-16 | Erik Dahlgren | ENZYM PAPERS FOR INDICATING CHOLINE ESTIMATE INHIBITORS WHICH ARE ENZYMED IMMOBILIZED BY AN ANION EXCHANGE, PROCEDURE FOR ITS PREPARATION AND USE OF PAPER WITH A SUBSTRATE |
FR2719998B1 (en) * | 1994-04-08 | 1996-09-27 | Pasteur Merieux Serums Vacc | Anti-helicobacter pylori immunizing composition based on catalase. |
US5716791A (en) * | 1996-05-09 | 1998-02-10 | Meridian Diagnostics, Inc. | Immunoassay for H. pylori in fecal specimens |
JP3640278B2 (en) * | 1996-12-20 | 2005-04-20 | 日本化薬株式会社 | Assay apparatus and assay method using the same |
-
2002
- 2002-04-23 WO PCT/JP2002/004011 patent/WO2002088737A1/en active Application Filing
- 2002-04-23 JP JP2002585986A patent/JP4443117B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO2002088737A1 (en) | 2002-11-07 |
JPWO2002088737A1 (en) | 2004-08-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5262156A (en) | Antigenic compositions and their use for the detection of Helicobacter pylori | |
US4497899A (en) | Immunoassay for Chlamydia trachomatis antigens | |
JP3969722B2 (en) | Candida detection | |
AU614608B2 (en) | Process for preparation of high molecular weight cell- associated protein of campylobacter pylori and use for serological detection of campylobacter pylori infection | |
JPH05264553A (en) | Antigen prepared for detecting helicobacter pyroly | |
US6849419B1 (en) | Monoclonal antibody hybridoma immunoassay method and diagnosis kit | |
Byzova et al. | Development of an immunochromatographic test system for the detection of Helicobacter pylori antigens | |
JP4268358B2 (en) | Antibody and immunological assay | |
RU2642588C1 (en) | Immunochromatographic test system for pathogenic helicobacter pylori strains detection | |
EP0868665A1 (en) | Fecal test method and device | |
CA1221628A (en) | Determination of streptococci | |
JP4443117B2 (en) | Immunochromatographic specimen and diagnostic kit | |
JP4406656B2 (en) | Mycobacterium tuberculosis detection method | |
JP4269006B2 (en) | Mycobacterium tuberculosis detection method | |
EP1278065A1 (en) | Method of detecting streptococcus sobrinus and antibody therefor | |
JPS60186759A (en) | Chromogen carrier immunoassay | |
RU2376604C2 (en) | Method for detection of antigen or antibody in immune-enzyme analysis | |
JP2000088854A (en) | High sensitive immunological detection measuring method for microorganism (bacteria, fungus, virus, producing substance) and quantitative method | |
KR970007080B1 (en) | Self-contained multiimmunoassay diagnostic system | |
JP4478658B2 (en) | Mycobacterium tuberculosis detection kit | |
JP2017036917A (en) | Method of detecting helicobacter pylori | |
JP4763149B2 (en) | Test method to determine infection with Helicobacter pylori | |
CA2032959A1 (en) | Article, test kit and sandwich assay for the detection of bacteroides intermedius, bacteroides gingivalis or actinobacillus actinomycetemcomotams | |
KR100254414B1 (en) | Mycobacterium tuberculosis antigen detection kit containing anti-m. tuberculosis antibody and anti-m. leprae antiserum | |
JP3504633B2 (en) | Test method and test reagent for determining infection to Helicobacter pylori |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050415 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050415 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20060915 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080422 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080618 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081021 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090716 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20090716 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091013 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100105 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4443117 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130122 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130122 Year of fee payment: 3 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130122 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140122 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |